COVID-19 virus can stay in the body more than a year after infection

The scientists found pieces of SARS-CoV-2, referred to as COVID antigens, lingering in the blood up to 14 months after infection and for more than two years in tissue samples from people who had COVID.

“These two studies provide some of the strongest evidence so far that COVID antigens can persist in some people, even though we think they have normal immune responses,” said Michael Peluso, MD, an infectious disease researcher in the UCSF School of Medicine, who led both studies.

The findings were presented at the Conference on Retroviruses and Opportunistic Infections (CROI), which was held March 3 to 6, 2024, in Denver.

Evidence of long-term infection

Early in the pandemic, COVID-19 was thought to be a transient illness. But a growing number of patients, even those who had previously been healthy, continued having symptoms, such as, brain fog, digestive problems and vascular issues, for months or even years.

The researchers looked at blood samples from 171 people who had been infected with COVID. Using an ultra-sensitive test for the COVID “spike” protein, which helps the virus break into human cells, the scientists found the virus was still present up to 14 months later in some people.

Among those who were hospitalized for COVID, the likelihood of detecting the COVID antigens was about twice as high as it was for those who were not. It was also higher for those who reported being sicker, but were not hospitalized.

“As a clinician, these associations convince me that we are on to something, because it makes sense that someone who had been sicker with COVID would have more antigen that can stick around,” Peluso said.

Virus persists up to two years in tissue

Since the virus is believed to persist in the tissue reservoirs, the scientists turned to UCSF’s Long COVID Tissue Bank, which contains samples donated by patients with and without long COVID.

They detected portions of viral RNA for up to two years after infection, although there was no evidence that the person had become reinfected. They found it in the connective tissue where immune cells are located, suggesting that the viral fragments were causing the immune system to attack. In some of the samples, the researchers found that the virus could be active.

Peluso said more research is needed to determine whether the persistence of these fragments drives long COVID and such associated risks as heart attack and stroke.

But, based on these findings, Peluso’s team at UCSF is involved in multiple clinical trials that are testing whether monoclonal antibodies or antiviral drugs can remove the virus and improve the health of people with long COVID.

“There is a lot more work to be done, but I feel like we are making progress in really understanding the long-term consequences of this infection,” Peluso said.

Authors: Additional UCSF co-authors include Sarah Goldberg, MAS, Brian H. LaFranchi, Scott Lu, MD, Thomas Dalhuisen, MS, Badri Viswanathan, Ma Somsouk, MD, MAS, J.D. Kelly, MD, Steven G. Deeks, MD, Zoltan Laszik, MD, PhD, Jeffrey Martin, MD, MPH, and Timothy J. Henrich, MD.

Funding: The studies were supported by funding from the PolyBio Research Foundation to support UCSF’s Long-Term Impact of Infection with Novel Coronavirus (LIINC) Clinical Core and a Merck Investigator Studies Program Grant. The National Institute of Health’s National Institute of Allergy and Infectious Diseases also provided funding (3R01AI1411003-03S1, R01AI158013 and K23AI134327, K23AI157875 and K24AI145806). Additional support came from the Zuckerberg San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases and Global Medicine.